Endocrine therapy for hormone receptor-positive advanced metastatic breast cancer

doi:10.3877/cma.j.issn.1674-0807.2018.02.002

Abstract

Abstract:

For the patients with advanced metastatic breast cancer, clinical treatment aims to relieve the symptoms, improve quality of life and prolong patients' survival. Endocrine therapy has mild adverse reactions and good efficacy, regarded as the first choice of hormone receptor-positive advanced breast cancer patients without visceral crisis. Endocrine therapy may eventually lead to drug resistance. How to postpone the drug resistance, put off the chemotherapy and reduce the pain is currently the hotspot of clinical research. In this paper, we summarized the latest research advancement in endocrine therapy and its combination with small molecule targeted drugs for pre- and post-menopausal hormone receptor-positive advanced metastatic breast cancer, in order to provide a reference for breast surgeons.

Key words: Breast neoplasms, Neoplasm metastasis, Estrogen receptor modulators

Dezong Gao. Endocrine therapy for hormone receptor-positive advanced metastatic breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2018, 12(02): 69-72.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2018.02.002

https://zhrxbzz.cma-cmc.com.cn/EN/Y2018/V12/I02/69

References 28

[1]	Huang HJ, Neven P, Drijkoningen M, et al. Association between tumor characteristics and HER2/neu by immunohistochemestry in 1362 women with primary operable breast cancer [J]. Clin Pathol, 2005, 58(6): 611-616.
[2]	Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005, 365(9472): 1687-1717.
[3]	Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer(ABC2) [J]. Breast, 2014, 23(5): 489-502.
[4]	Schiavon G, Smith IE. Endocrine therapy for advanced/metastatic breast cancer [J]. Hematol Oncol Clin North Am, 2013, 27(4): 715-736.
[5]	Lønning PE, Eikesdal HP. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved [J]. Endocr Relat Cancer, 2013, 20(4): R183-201.
[6]	Miller WR, Bartlett J, Brodie AM, et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter？[J]. Oncologist, 2008, 13(8): 829-837.
[7]	Mauri D, Pavlidis N, Polyzos NP, et al. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis[J]. J Natl Cancer Inst, 2006, 98(18): 1285-1291.
[8]	Xu HB, Liu YJ, Li L. Aromatase inhibitor versus tamoxifen in postmenopausal woman with advanced breast cancer: a literature-based meta-analysis[J]. Clin Breast Cancer, 2011, 11(4): 246-251.
[9]	Di Leo A, Jerusalem G, Petruzelka L, et al. Bondarenk results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2010, 28(30): 4594-4600.
[10]	Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST’ study[J]. Breast Cancer Res Treat, 2012, 136(2): 503-511.
[11]	Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase Ⅱ FIRST study[J]. J Clin Oncol, 2015, 33(32): 3781-3787.
[12]	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer[J]. Nat Genet, 2013, 45(12): 1446-1451.
[13]	Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TAnDEM study[J]. J Clin Oncol, 2009, 27(33): 5492-5494.
[14]	Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2014, 32(19): 2078-2099.
[15]	Narasimha AM, Kaulich M, Shapiro GS, et al. Cyclin D activates the Rb tumor suppressor by mono－phosphorylation[EB/OL]．[2016－08－19]. URL
[16]	Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast Cancer[J]. N Engl J Med, 2015, 373(3): 209-219.
[17]	Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 Study [J]. Lancet Oncol, 2015, 16(1): 25-35.
[18]	Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet Oncol, 2016, 17(4): 425-439.
[19]	Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor positive advanced breast cancer[J]. N Engl J Med, 2012, 366(6): 520-529.
[20]	Piccart M, Hortobahyi G, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: overall survival results from BOLERO-2[J]. Ann Oncol, 2014, 25(12): 2357-2362.
[21]	Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(＋) breast cancer: BOLERO-2 final progression-free survival analysis[J]. Adv Ther, 2013, 30(10): 870-884.
[22]	Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline[J]．J Clin Oncol, 2016, 34(25): 3069-3103.
[23]	Wolff A, Lazar A, Bondarenko I, et al. Randomized phase Ⅲ placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer[J]. J Clin Oncol, 2013, 31(2): 195-202.
[24]	Kümler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer[J]. Cancer Treat Rev, 2014, 40(8): 960-973.
[25]	Martín M, Loibl S, Von Minckwitz G, et al. Phase Ⅲ trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study[J]. J Clin Oncol, 2015, 33(9): 1045-1052.
[26]	Klijn JG, Blamey RW, Boccardo F, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials[J]. J Clin Oncol, 2001, 19(2): 343-353.
[27]	Carlson RW, Theriault R, Schurman C, et al. Phase Ⅱ trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women[J]. J Clin Oncol, 2010, 28(25): 3917-3921.
[28]	Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J]. N Engl J Med, 2014, 371(2): 107-118.

Please choose a citation manager

Content to export